Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Fig. 8

Cumulative ranking probability of progression-free survival (PFS) for the treatment of metastatic breast cancer. A = Tax, B = Cap, C = Bev + Tax, D = Bev + Cap, E = Bev + Exm, F = Mot + Tax, G = Bev + Tax+Cap, H = Bev + Cap+Cyc, I = Bev + Cap+Vin, J = Bev + Tax+Eve, K = Bev + Tax+Tre. Bev = bevacizumab, Cap = capecitabine, Tax = taxanes, Vin = vinorelbine, Cyc = cyclophosphamide, Exm = exemestane, Eve = everolimus, Tre = trebananib, Mot = motesanib. Serial number 1–11 represent probability ranking

Back to article page
\